RARE DISEASERESEARCH ATLAS

ORPHA:448010

CAD-CDG

medium confidenceDisorder

Also known as: CDG syndrome type Iz · CDG-Iz · CDG1Z · Carbohydrate deficient glycoprotein syndrome type Iz · Congenital disorder of glycosylation type 1z

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

41

50.1th percentile

Trials

0

Interventional, condition-specific

Researchers

235

Distinct authors in sample

Gene link

CAD

Definitive

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare disorder of glycosylation caused by mutations in the CAD gene and characterized by epileptic , global , normocytic anemia and anisopoikilocytosis. Loss of acquired skills in early childhood is present and natural disease course can be lethal in early childhood.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (6)

DEE50 · EIEE50 · carbohydrate deficient glycoprotein syndrome type Iz · congenital disorder of glycosylation type 1z · developmental and epileptic encephalopathy 50 · epileptic encephalopathy, early infantile, 50

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — CAD

  2. LiteraturePresent

    41 matched papers (41 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (CAD).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

41

41 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

41 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

41 in the last 10 years · medium confidence · 50.1th percentile (publications denominator)

Phrase hits: 41 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

235

Distinct author names in 41 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Morava E6 papers · 2023

    Metabolic Center, Department of Pediatrics, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium. Morava-Kozicz.Eva@MAYO.edu.

    Papers in Europe PMC
  2. 02
    Freeze HH5 papers · 2024

    Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. Electronic address: hudson@sbpdiscovery.org.

    Papers in Europe PMC
  3. 03
    Jaeken J5 papers · 2023

    Metabolic Center, Department of Pediatrics, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium.

    Papers in Europe PMC
  4. 04
    Ng BG5 papers · 2024

    Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.

    Papers in Europe PMC
  5. 05
    Andreotti G3 papers · 2023

    Istituto di Chimica Biomolecolare-Consiglio Nazionale delle Ricerche (CNR), 80078 Pozzuoli, Italy. gandreotti@icb.cnr.it.

    Papers in Europe PMC
  6. 06
    Ferreira CR3 papers · 2024

    Medical Genetics Branch National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

    Papers in Europe PMC
  7. 07
    Francisco R3 papers · 2022

    UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Lisboa, Portugal.

    Papers in Europe PMC
  8. 08
    He M3 papers · 2026

    Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

    Papers in Europe PMC
  9. 09
    Bao X2 papers · 2024

    Department of Pediatrics, Peking University First Hospital, Beijing, 100034, China. zwhang@pku.edu.cn.

    Papers in Europe PMC
  10. 10
    Brasil S2 papers · 2022

    Portuguese Association for Congenital Disorders of Glycosylation (CDG), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2820-287 Lisboa, Portugal. s.arduim@gmail.com.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"CAD-CDG" OR "CDG syndrome type Iz" OR "CDG-Iz" OR "CDG1Z" OR "Carbohydrate deficient glycoprotein syndrome type Iz" OR "Congenital disorder of glycosylation type 1z" OR "Congenital disorder of the glycosylation type 1z" OR "DEE50" OR "EIEE50" OR "developmental and epileptic encephalopathy 50" OR "epileptic encephalopathy, early infantile, 50"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"CAD-CDG" OR "CDG syndrome type Iz" OR "CDG-Iz" OR "CDG1Z" OR "Carbohydrate deficient glycoprotein syndrome type Iz" OR "Congenital disorder of glycosylation type 1z" OR "Congenital disorder of the glycosylation type 1z" OR "DEE50" OR "EIEE50" OR "developmental and epileptic encephalopathy 50" OR "epileptic encephalopathy, early infantile, 50" OR "CAD"

Recall-expansion terms: CAD

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T16:36:04.549Z